SecBot SecBot
8-K ·Filed Oct 13, 2026

SSII

SS Innovations International, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed13d 10h ago SEC0001213900-26-108624
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The aggressive terms (95% conversion discount, 8.75% interest, Make-Whole Interest, Trigger Effect penalties, IP collateral) indicate distressed financing. Monitor for early conversion activity and any Trigger Events that could accelerate dilution. The 4-day gap between the 424B5 and this 8-K suggests this was a pre-arranged financing package — watch for additional draws or amendments.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+5d
SSII ▼ -0.39% at T+5d
SHORT call ✓ call won +0.39% · α vs SPY -0.76% · entry $2.55 → $2.54
Next anchor: T+20d in 15d
Latest observation: T+8 +5.11% FF3 residual α
Entry = T+0 close
Oct 13, 2026
via day close
T+1d
+5.88%
call -5.88% · α -6.96%
$2.70
settled 12d ago
T+5d
-0.39%
call +0.39% · α -0.76%
$2.54
settled 6d ago
T+20d
Pending
in 15d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

SS Innovations International issued a $21.025M secured convertible promissory note to Growth Capital Partners, LLC, receiving $20M in net proceeds after a $1M OID and $25K in transaction expenses. The note carries 8.75% interest, matures in 36 months, and is secured by substantially all assets of the company and its subsidiaries (excluding the Indian operating subsidiary SSI-India), including a first-priority lien on the company's intellectual property portfolio. This financing follows a $20M convertible note offering filed just 4 days prior (October 9, 2026), indicating a capital raise to fund operations or growth initiatives.

Key Financial Metrics

Deal Value
$21.0M
Deal Type
credit_facility

Key Facts

  • $21.025M secured convertible promissory note issued to Growth Capital Partners, LLC
  • Net proceeds of $20M after $1M OID and $25K transaction expense
  • 8.75% interest rate, compounding daily, 36-month maturity
  • Conversion price set at 95% of the lower of: (a) 1-day VWAP or (b) 5-day average VWAP
  • Security includes first-priority lien on all assets of SSII and SSI IP Holdings, including all IP (patents, trademarks, copyrights)
  • Indian operating subsidiary (SSI-India) explicitly excluded from collateral
  • Subsidiaries guaranteeing the note: SSI IP Holdings, CardioVentures Inc., Avra IP Holdings, Otto Pvt. Ltd., SS International Centre for Robotics Surgery
  • Lender can redeem up to $50K or 10% of daily dollar volume on days stock trades 10% above market price (Limited Redemption)
  • After 12 months, lender can redeem up to 1/24th of outstanding balance per month (Fixed Redemption)
  • Trigger events include: failure to pay, insolvency, fundamental transaction without consent, breach of covenants, failure to maintain registration statement, failure to deliver conversion shares, reverse split without notice, judgment >$2.5M, loss of DWAC eligibility
  • Trigger events allow 15% balance increase (Major) or 5% (Minor), up to 3 each
  • Default interest rate: 18% per annum
  • Company reserved 8M shares for conversion, with requirement to maintain reserve at 3x conversion shares
  • Exchange Cap under Nasdaq Rule 5635(d) applies unless shareholder approval obtained
  • Company covenants not to issue variable-rate securities or incur debt >$40M without lender consent
  • This filing follows a $20M convertible note offering filed on October 9, 2026 (424B5)

Financial Impact

$20M net cash inflow from $21.025M convertible note; potential dilution from conversion at 95% of market price; IP collateral pledged as security

debtdilutioncashintellectual property

Risk Factors

  • Significant dilution risk — conversion at 95% of market price with Make-Whole Interest could result in substantial share issuance
  • IP collateral pledged as security — loss of IP in default scenario would destroy company value
  • Restrictive covenants limit future financing flexibility — no variable-rate transactions, debt cap of $40M
  • Trigger Event penalties (15%/5% balance increases) create potential for rapid debt escalation
  • Exchange Cap may limit conversion, forcing cash repayment that company may not have
  • Indian subsidiary (SSI-India) excluded from collateral — potential structural subordination risk for lender

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-108624
Document: ea030806201ex10-1.htm0001213900-26-108624
Document: ea030806201ex4-1.htm0001213900-26-108624
Document: ea030806201ex10-3.htm0001213900-26-108624
Document: ea030806201ex10-4.htm0001213900-26-108624
22 reports for SSII
Performance horizon
50% Hit rate @ T+5 2 of 4 directional calls Went positive at some point 3 of 4 best @ T+20▲ +15.17%May 20, 2026
Filters
Rows
Reports for SSII — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
NEUTRAL ★ 3/10
—awaiting T+5——
Oct 26, 2026
today
Press Release
NEUTRAL ★ 3/10
—awaiting T+5——
Oct 13, 2026
13d ago
8-K
NEUTRAL ★ 4/10
$2.55 $2.54▼ −0.39%▲ +0.76%$2.37 (−7.06%)
Oct 13, 2026
13d ago
8-K
BEARISH ★ 6/10
$2.55 $2.54▲ +0.39%▼ −0.76%$2.37 (+7.06%)
Oct 9, 2026
16d ago
424B5
BEARISH ★ 6/10
$2.55 $2.45▲ +3.92%▲ +2.43%$2.37 (+7.06%)
Oct 5, 2026
21d ago
8-K
NEUTRAL ★ 4/10
$2.77 $2.55▼ −7.94%▼ −8.36%$2.37 (−14.44%)
Sep 10, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$3.30 $3.26▼ −1.21%▼ −0.71%$2.37 (−28.18%)
Aug 13, 2026
10w ago
8-K
MIXED ★ 6/10
$3.83 $3.61▼ −5.74%▼ −3.78%$2.37 (−38.12%)
Jul 17, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$3.64 $3.57▼ −1.92%▼ −1.24%$2.37 (−34.89%)
Jul 14, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$3.67 $3.75▲ +2.18%▲ +3.48%$2.37 (−35.42%)
Showing 10 of 22

US Market Status

Market Closed — Opens Tue (16h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 13, 2026